Abstract
The efforts now being made in the pharmaceutical industry to apply recombinant DNA techniques to the large-scale production of medically useful biologicals require that procedures be developed for the standardization and control of these products. These procedures will need to test the identity, purity, and stability of the plasmid, the reliability of the procedure used in the preparation of the seed clone of bacteria, and all intermediate and final products. In many cases, new techniques will have to be developed for this testing. Some of the factors will be safeguarded by inprocess control, but great reliance will be placed on tests of the final product. The present article outlines the tests that would be appropriate for the control of the safety and efficacy of recombinant DNA products; it is aimed mainly at scientists and administrators in countries not involved in the production of such biologicals, to inform them of the problems involved in their control.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Burrell C. J., Mackay P., Greenaway P. J., Hofschneider P. H., Murray K. Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322. Nature. 1979 May 3;279(5708):43–47. doi: 10.1038/279043a0. [DOI] [PubMed] [Google Scholar]
- Chance R. E., Kroeff E. P., Hoffmann J. A., Frank B. H. Chemical, physical, and biologic properties of biosynthetic human insulin. Diabetes Care. 1981 Mar-Apr;4(2):147–154. doi: 10.2337/diacare.4.2.147. [DOI] [PubMed] [Google Scholar]
- Crainic R., Horodniceanu F., Barme M. Quantitation of cell DNA in the evaluation of heteroploid cells as substrate for the preparation of killed viral vaccines. Intervirology. 1980;14(5-6):300–309. doi: 10.1159/000149200. [DOI] [PubMed] [Google Scholar]
- Goeddel D. V., Yelverton E., Ullrich A., Heyneker H. L., Miozzari G., Holmes W., Seeburg P. H., Dull T., May L., Stebbing N. Human leukocyte interferon produced by E. coli is biologically active. Nature. 1980 Oct 2;287(5781):411–416. doi: 10.1038/287411a0. [DOI] [PubMed] [Google Scholar]
- Hitzeman R. A., Leung D. W., Perry L. J., Kohr W. J., Levine H. L., Goeddel D. V. Secretion of human interferons by yeast. Science. 1983 Feb 11;219(4585):620–625. doi: 10.1126/science.6186023. [DOI] [PubMed] [Google Scholar]
- Nagata S., Taira H., Hall A., Johnsrud L., Streuli M., Ecsödi J., Boll W., Cantell K., Weissmann C. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature. 1980 Mar 27;284(5754):316–320. doi: 10.1038/284316a0. [DOI] [PubMed] [Google Scholar]
- Oldham R. R. Toxic effects of interferon. Science. 1983 Feb 25;219(4587):902–902. doi: 10.1126/science.6186027. [DOI] [PubMed] [Google Scholar]
- Olson K. C., Fenno J., Lin N., Harkins R. N., Snider C., Kohr W. H., Ross M. J., Fodge D., Prender G., Stebbing N. Purified human growth hormone from E. coli is biologically active. Nature. 1981 Oct 1;293(5831):408–411. doi: 10.1038/293408a0. [DOI] [PubMed] [Google Scholar]